Intravitreal administration of vascular endothelial growth factor antagonists (anti-VEGF), mainly ranibizumab and aflibercept, became the gold standard of modern wet AMD therapy [2, 3]. The gene discussed is VEGFA; the disease is wet macular degeneration.